Archive for the ‘Bone Marrow Stem Cells’ Category

The bones of the skeletal system serve many important functions for the body, from giving your body support to allowing you to move. They also play an important role in blood cell production and fat storage.

Bone marrow is the spongy or viscous tissue that fills the inside of your bones. There are actually two types of bone marrow:

Read on to learn more about different functions of red and yellow bone marrow as well as the conditions that affect bone marrow.

Red bone marrow is involved in hematopoiesis. This is another name for blood cell production. Hematopoietic stem cells that are found in red bone marrow can develop into a variety of different blood cells, including:

Newly produced blood cells enter your bloodstream through vessels called sinusoids.

As you age, your red bone marrow is gradually replaced with yellow bone marrow. And by adulthood, red bone marrow can be found only in a handful of bones, including the:

Yellow bone marrow is involved in the storage of fats. The fats in yellow bone marrow are stored in cells called adipocytes. This fat can be used as an energy source as needed.

Yellow bone marrow also contains mesenchymal stem cells. These are cells that can develop into bone, fat, cartilage, or muscle cells.

Remember, over time, yellow bone marrow starts to replace red bone marrow. So, most bones in an adult body contain yellow bone marrow.

Bone marrow is crucial for producing blood cells. Therefore, a range of blood-related conditions involve issues with bone marrow.

Many of these conditions affect the numbers of blood cells produced in bone marrow. This causes them to share many common symptoms, including:

Heres a look at some specific conditions involving bone marrow issues.

Leukemia is a type of cancer that can affect both your bone marrow and lymphatic system.

It happens when blood cells get mutations in their DNA. This causes them to grow and divide more rapidly than healthy blood cells. Over time, these cells start to crowd out the healthy cells in your bone marrow.

Leukemia is classified as either acute or chronic, depending on how fast it progresses. Its further broken down by the type of white blood cells it involves.

Myelogenous leukemia involves red blood cells, white blood cells, and platelets. Lymphocytic leukemia involves lymphocytes, a specific type of white blood cell.

Some of the major types of leukemia include:

Theres no clear cause of leukemia, but certain things can increase your risk, including:

Aplastic anemia occurs when bone marrow doesnt produce enough new blood cells. It occurs from damage to the stem cells of bone marrow. This makes it harder from them to grow and develop into new blood cells.

This damage can be either:

Myeloproliferative disorders happen when the stem cells in bone marrow grow abnormally. This can lead to increased numbers of a specific type of blood cell.

There are several types of myeloproliferative disorders, including:

Bone marrow is found in the bones throughout your body. There are two types of bone marrow. Red bone marrow is involved in production of blood cells, while yellow marrow is important for fat storage. As you age, yellow bone marrow replaces red bone marrow.

Read more from the original source:
Function of Bone Marrow: What Is Bone Marrow, and What ...

Patients with cancer often incur bone marrow damage, resulting in the destruction of stem cells. Stem cell transplants are used to replenish lost or damaged cells that have been affected by cancer and depending on where the stem cells come from these, the procedure may be a bone marrow transplant (BMT), peripheral blood stem cell transplant, or a cord blood transplant.

Typically, in a stem cell transplant, physicians administer high doses of chemotherapy, occasionally in conjunction with radiation therapy, to kill all cancer cells. This is known as myeloablative therapy.

Here are the two main types of transplants, as outline by the American Cancer Society:

In an autologous stem cell transplant, the patient serves as their own donor. Auto means self, therefore this procedure means harvesting your own stem cells from either your blood or bone marrow, then freezing them for preservation. Following high-dose chemo and radiation therapy, the frozen cells are thawed and returned to the (self) donor. Autologous transplants are sometimes used for testicular cancer and brain tumors, but are mainly utilized to treat leukemia, lymphoma, and multiple myeloma. For the latter, autologous stem cell procedures offers patients a chance for achieving sustained remission. One advantage of autologous stem cell transplant is that youre getting your own cells back. When you getyour own stem cells back, you dont have to worry about them (called the engrafted cells or the graft) being rejected by your body, says the American Cancer Society.

Despite the benefits, as with all procedures, there are risks involved, including graft failure which occurs when the transplanted stem cells dont go into bone marrow fail to properly produce blood cells. A possible disadvantage of an autologous transplant is that cancer cells might be collected along with the stem cells and then later put back into your body, the ACS says, adding that another disadvantage of a autologous stem cell transplants is that your immune system is the same as it was before your transplant. This means the cancer cells were able to escape attack from your immune system before, and may be able to do so again.

But how exactly do physicians prevent any residual cancer cells from being transplanted with healthy cells? In a process known as purging, stem cells are treated before being infused back into the patients blood. Although purging carries its benefits, a potential downside, according to the ACS, is that normal cells may be lost during this process, which in turn could lead to unsafe levels of white blood cells as your body takes longer to produce normal blood cells. Cancer centers will also sometimes use in vivopurging, which involves not treating the stem cells, and instead administering anti-cancer drugs to patients post-transplant. The ACS notes, however, that the need to remove cancer cells from transplanted stem cells or transplant patients and the best way to do it continues to be researched.

Whereas autologous procedures infuse stem cells from your own body, allogeneic stem cell transplants use cells from a donor with a very similar tissue type (in many cases a relative, usually a sibling). In cases where the ideal donor is not a relative, physicians may opt to perform a matched unrelated donor (MUD) transplant, which as the ACS notes, are usually riskier than those with a relative who is a good match.

Allogeneic transplants comprise of the same process as autologous stem cell transplants where stem cells are harvested, frozen, and subsequently thawed and put back following high-dose chemo and/or radiation therapy. In some cases, the procedures involve the infusion of blood extracted from the placenta and umbilical cord of a newborn because the cord contains a high number of stem cells that quickly multiple. By 2017, an estimated 700,000 units (batches) of cord blood had been donated for public use. And, even more have been collected for private use. In some studies, the risk of a cancer not going away or coming back after a cord blood transplant was less than after an unrelated donor transplant, writes the ACS.

A benefit of an allogeneic transplant is that donor stem cells create their own immune cells, which may eliminate any residual cancer cells that remain after high-dose treatment, which is known as the graft-versus-cancer effect. Moreover, because the donor stem cells are free of cancer, donors can be asked to donate stem cells or white blood cells multiple times.

As with autologous stem cell procedures, this donor dependent transplant also carries risk. The transplant, or graft, might be destroyed by the patients body before reaching the bone marrow. Allogeneic stem cell transplants also augment the risk of graft-versus-host-disease, where cells from the donor attack healthy cells in the recipients body. Furthermore, despite the healthy cells being tested before transplant, allogeneic procedures still carry a certain risk of infections because, as the ACS writes, your immune system is held in check (suppressed) by medicines calledimmunosuppressivedrugs. Such infections can cause serious problems and even death.

Because theres a plethora of human leukocyte antigen (HLA) combinations, which are inherited from both parents, finding an exact donor match can often be an arduous task. The search usually starts at siblings, and theres a 25% chance of a sibling being a perfect match. In the event that a sibling does not match, the search moves onto extended family (and parents) who are less likely to match.

The ACS writes: As unlikely as it seems, its possible to find a good match with a stranger. To help with this process, the team will use transplant registries, like those listed here. Registries serve as matchmakers between patients and volunteer donors. They can search for and access millions of possible donors and hundreds of thousands of cord blood units.

Go here to read the rest:
The Two Types of Stem Cell Transplants for Cancer Treatment - DocWire News

Stem cell characterization is the study of tissue-specific differentiation. Thera are various type of stem cell such as embryonic stem cell, epithelial stem cell and others. Further, various techniques are used to characterized stem cells such as immunological techniques, used for depiction of different population of stem cells. These techniques are generally based on immunochemistry using staining technique or florescent microscopy. Besides, stem cells characterization and analysis tools are used against target chronic diseases. In 2014, the San Diego (UCSD) Health System and Sanford Stem Cell Clinical Center at the University of California announced the launch of a clinical trial, in order to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/31444

The factors driving the growth of stem cell characterization and analysis tools market due to increasing chronic disorders such as cancer, a diabetes and others. In addition, increasing awareness about among people about the therapeutic potency of stem cells characterization in the management of effective diseases is anticipated to increase the demand for stem cell characterization and analysis tools. Further, there are various technologies such as flow cytometry which is used to characterize the cell surface profiling of human-bone marrow and other related purposes are expected to increase the growth of stem cell characterization and analysis tools market. In addition, increasing investment by private and public organization for research activities are likely to supplement the market growth in near future.

On the other hand, the unclear guidelines and the technical limitation for the development of the product are expected to hamper the growth of stem cell characterization and analysis tools market.

Rapid increase in corona virus all around the world is expected to hamper the growth of stem cell characterization and analysis tools market. The virus outburst has become one of the threats to the global economy and financial markets. The impact has made immense decrease in revenue generation in the field of all healthcare industry growth for the market in terms of compatibility and it has led in huge financial losses and human life which has hit very hard to the core of developing as well as emerging economies in healthcare sector. It further anticipated that such gloomy epidemiological pandemic environment is going to remain in next for at least some months, and this is going to also affect the life-science market which also include the market of stem cell characterization and analysis tools market.

Based on the Products and Service Type, stem cell characterization and analysis tools market are segmented into:

Based on the Technology, stem cell characterization and analysis tools market are segmented into:

Based on the Applications, stem cell characterization and analysis tools market are segmented into:

Based on the End User, stem cell characterization and analysis tools market are segmented into:

Based on the segmentation, human embryonic stem cell is expected to dominate the market due to their indefinite life span and higher totipotency as compared to other stem cells. Further, on the basis of technology segmentations, cell production is anticipated to increase the demand for stem cell characterization and analysis tools due to their emerging applications for stem cells in drug testing in the management of the effective diseases. Furthermore, on the basis of application segmentations, oncology is expected to show significant growth rate due to increase in the number of pipelines products for the treatment of cancers or tumors. Based on the end user, pharmaceutical and biotechnology companies are expected to dominate the market due to rising global awareness about the therapeutics research activities.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/31444

Geographically, the global stem cell characterization and analysis tools market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global stem cell characterization and analysis tools market due to growing cases of target chronic diseases and increasing investments for research activities. Europe is the second leading region to dominate the market due to technological advancement and also surge in therapeutic activities, funded by government across the world. Asia-pacific is likely to witness maximum growth in near future due to increasing disposable income and with the development of infrastructure.

Some of the major key players competing in the global stem cell characterization and analysis tools market are Osiris Therapeutics, Inc., Caladrius Biosciences, Inc., U.S. Stem Cell, Inc., Astellas Pharma Inc., TEMCELL Technologies Inc., BioTime Inc., Cellular Engineering Technologies Inc., Cytori Therapeutics, Inc., and BrainStorm Cell Therapeutics Inc.

Go here to read the rest:
Impact of COVID 19 pandemic on Stem Cell Characterization and Analysis Tools Market Structure and Its Segmentation - 3rd Watch News

When you compare pictures of presidents who do not alter their hair color, they all leave office considerably grayer than when they started, which some link to the stress of the office.

Marie Antoinette syndrome is a condition in which scalp hair suddenly turns white. The name comes from the story that Marie Antoinettes hair turned white the night before she was to face the guillotine during the French Revolution.

The same thing happened to survivors of atomic bomb attacks during World War II. It has long been thought that genetics, aging and stress all contribute to developing gray hair.

New research has revealed how stress contributes to graying.

On average, humans have 100,000 hair follicles in their scalp, which produce hairs of one color or another. Hair color is determined by the types of melanin produced by cells called melanocytes. Melanocytes grow from melanocyte stem cells (MeSCs) inside the hair follicle.

With age, the number of MeSCs declines, leading to hair graying in stages from the occasional gray one, to salt and pepper, to gray and then white when all the MeSCs are gone. But how stress leads to gray hair has been a mystery.

It had been thought that stress-induced graying involved hormones such as corticosterone or autoimmune reactions. Scientists did experiments in mice and found that neither of those was the cause.

However, when they blocked the receptor for the fight-or-flight hormone, noradrenaline, they stopped hair graying in response to stress in mice. Finally, they had a clue.

The main source of noradrenaline is the adrenal glands. However, when the scientists removed the adrenal glands in mice, their hair still turned gray in response to stress. Another source of the hormone is the sympathetic nervous system (SNS), which is part of the autonomic nervous system that works to regulate many functions and parts of the body without us thinking about it.

The SNS controls the fight-or-flight response to stress to prepare the whole body for physical activity. SNS nerves and MeSCs are close together in the hair follicle, and blocking those SNS nerves prevented the hairs from turning gray in response to stress. Conversely, when the SNS nerves were over-activated, the mice went gray even without stress.

Normally, MeSCs are dormant unless hair is regrowing. In response to extreme stress, MeSCs reproduce and mature into melanocytes quickly. Large numbers of melanocytes then migrate from the follicle, leaving no MeSCs in the follicles and no melanocytes to provide the pigments that give hair its color. Once they are all gone, hair will never be its original color again.

This brings up the added question about other effects of stress, including a decline in immunity and the ability to fight off infections.

The SNS system also stimulates stem cells in the bone marrow to mature into the blood cells required to protect us from infections. Nearly every organ in the body contains stem cells, and stress could have an impact on those as well.

Medical Discovery News is hosted by professors Norbert Herzog at Quinnipiac University, and David Niesel of the University of Texas Medical Branch. Learn more at http://www.medicaldiscoverynews.com.

Read the original:
How stress contributes to the graying of hair - Galveston County Daily News

- Partnership leverages Boehringer Ingelheims oncology expertise to lead trilaciclib SCLC launch sales engagements- G1 to retain full development and commercialization rights and book revenue for trilaciclib-New Drug Application (NDA) for trilaciclib submitted in June 2020

RESEARCH TRIANGLE PARK, N.C. and RIDGEFIELD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX) and Boehringer Ingelheim today announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer (SCLC), with the Boehringer Ingelheim oncology commercial team, well-established in lung cancer, leading sales force engagement initiatives. Discovered and developed by G1, trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

We believe that trilaciclib has the potential to benefit patients with cancer being treated with chemotherapy across a broad range of solid tumors, said Mark Velleca, M.D., Ph.D., Chief Executive Officer of G1. Our clinical trials of trilaciclib in small cell lung cancer have demonstrated significant myelopreservation benefits, and we are excited to collaborate with Boehringer Ingelheims experienced commercial oncology team to bring this innovative therapy to patients with SCLC. In addition, this capital efficient launch structure provides us with the ability to make investments in a robust development program to assess trilaciclib in other solid tumors, including colorectal cancer and breast cancer.

Under the terms of the agreement, G1 will book revenue in the United States and Puerto Rico and retain global development and commercialization rights to trilaciclib. In the U.S. and Puerto Rico, G1 will lead marketing, market access and medical engagement initiatives; Boehringer Ingelheim will lead sales force engagements. G1 will make initial payments to Boehringer Ingelheim to cover start-up expenses and pre-approval initiatives to support a successful commercial launch. G1 will pay a promotion fee of a mid-twenties percentage of net sales in the first year of commercialization, which decreases to a low double-digit/high single-digit percentage in the second and third years of commercialization, respectively (subject to certain adjustments for sales above pre-specified levels to reward out-performance). There are no payments due by either party beyond the expiration of the three-year term of the agreement. The agreement does not extend to additional indications that G1 may pursue for trilaciclib.

Boehringer Ingelheims commitment to transform treatment expectations for the oncology community extends beyond research and drives us to explore innovative solutions for patients. We are pleased to be collaborating with G1 Therapeutics and applying our commercial strengths focused on lung cancer to support a new therapy for patients with clear synergies across customer audiences, said Kelli Moran, Senior Vice President, Specialty Care, Boehringer Ingelheim. This strategic agreement builds on Boehringer Ingelheims achievements in oncology and contributes to our long-term vision to give patients new hopeby taking cancer on.

G1 received Breakthrough Therapy Designation for trilaciclib from the U.S. Food and Drug Administration (FDA) in 2019 and submitted a New Drug Application (NDA) in June 2020. More than 25,000 people in the U.S. and Puerto Rico are diagnosed with SCLC each year. Approximately 90% of SCLC patients receive first-line chemotherapy treatment, and approximately 60% of those patients receive subsequent second-line chemotherapy treatment. Chemotherapy is an effective and important weapon against cancer. However,chemotherapy does not differentiate between healthy cells and cancer cells and kills both. One of the most common side effects of chemotherapy is myelosuppression the result of damage to stem cells in the bone marrow that produce white blood cells, red blood cells and platelets. Myelosuppression often requires the administration of rescue interventions such as growth factors and blood or platelet transfusions, and may also result in chemotherapy dose delays and reductions. Immune cell damage may decrease the ability of the immune system to fight the cancer, as well as infection. Trilaciclib has the potential to be the first proactively administered myelopreservation therapy that can make chemotherapy safer and improve the patient experience.

Additional information regarding this agreement is disclosed in a Current Report on Form 8-K filed by G1 with the U.S. Securities and Exchange Commission (available here).

About TrilaciclibTrilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation based on positive myelopreservation data from three randomized, double-blind, placebo-controlled clinical trials in which trilaciclib was administered prior to chemotherapy treatment in patients with small cell lung cancer (SCLC). In a randomized trial of women with metastatic triple-negative breast cancer, trilaciclib improved overall survival when administered prior to chemotherapy. In June 2020, G1 submitted a New Drug Application (NDA) for trilaciclib for myelopreservation in SCLC and began a study in neoadjuvant breast cancer as part of the I-SPY 2 TRIAL. The company expects to initiate a Phase 3 trial in colorectal cancer in the fourth quarter of 2020.

About G1 TherapeuticsG1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit http://www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

About Boehringer Ingelheim in OncologyCancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are giving patients new hopeby taking cancer on. We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science.Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approachesto help combat many cancers.

About Boehringer IngelheimMaking new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of around $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.

Boehringer Ingelheim is committed to improving lives and strengthening our communities.Please visit http://www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives. For more information, please visit http://www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

G1 Therapeutics Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in theU.S. for trilaciclib in SCLC, trilaciclibs possibility to improve patient outcomes across multiple indications, rintodestrants potential to be best-in-class oral SERD, lerociclibs differentiated safety and tolerability profile over other marketed CDK4/6 inhibitors and the impact of pandemics such as COVID-19 (coronavirus), and are based on the companys expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the companys actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the companys filings with theU.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the companys ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the companys initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:Jeff MacdonaldG1 Therapeutics, Inc.Senior Director, Investor Relations & Corporate Communications919-907-1944jmacdonald@g1therapeutics.comSusan HolzBoehringer IngelheimDirector, Public Relations203-798-4265Susan.holz@boehringer-ingelheim.com

Visit link:
G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto...

Hematopoietic stem cell transplantation is a curative therapy for many patients suffering from life threatening blood disorders. This treatment is currently limited by the availability of compatible bone marrow donors and, as a result, transplant of unrelated donor umbilical cord blood is an attractive alternative.This approach has the advantages of rapid availability and reduced stringency for a complete donor/recipient match, but is limited by a relatively low number of stem cells within a single cord blood unit. One focus of the Stem Cell Regulators research group, led by Prof. Jonas Larsson, is the development of new strategies to expand stem cells ex vivo, allowing for the treatment of patients who otherwise would lack a suitable donor.

When grown outside the body hematopoietic stem cells proliferate and differentiate from an immature state to more mature blood cell types. explains Prof. Larsson. We aim to identify novel ways to counteract this maturation, pushing stem cells to self-renew and increase in numbers.

In a study published in the journal Blood, the Larsson group targeted the enzyme LSD1, part of the CoREST complex, known to mediate the epigenetic modification of DNA and pushing the differentiation of stem cells into mature blood cells.

We hypothesised that by reducing LSD1 levels using small molecule drugs we could halt stem cell differentiation and stimulate expansion. explains postdoctoral researcher Agatheeswaran Subramaniam and first author on the paper.

This turned out to be the case for both cord blood derived and adult bone marrow stem cells, with LSD1 inhibition expanding stem and progenitor cells from different sources and different stages of development.

To gain insights into how targeting LSD1 led to the expansion of stem cells, the group performed gene expression profiling. They compared LSD1 inhibition to treatment with UM171, a human hematopoietic stem cell promoting molecule identified in 2014 and currently in phase II clinical trials, despite an as yet unidentified mechanism of action. The gene signatures of LSD1 inhibition and UM171 treatment were strikingly similar.

The research group then postulated that these treatments could be working by the same mechanism.

Through a collaboration with Prof. Roman Zubarev at Karolinska Institute, the key targets of UM171 were established using a technique known as Thermal Proteome Profiling. This approach, which identifies interactions between small molecules and proteins, confirmed the direct binding of UM171 to LSD1, as well as to the core structural component of the CoREST complex, RCOR1.

Extensive analyses by Kristijonas emaitis, a PhD student in the Larsson lab, revealed that UM171 directs the components of the CoREST complex to degradation via the ubiquitin proteasome pathway, the system used by the cell to break down proteins.

In this study have we identified a novel target for human hematopoietic stem cell expansion ex vivo, as well as taking steps to understanding the previously undetermined mechanism of action of UM171. reflects Agatheeswaran. The most striking finding was the extremely rapid and efficient degradation of members of the CoREST complex by UM171.

What remains unclear is exactly how the CoREST complex is targeted and its degradation triggered. An understanding of this has the potential to reveal principles that can be exploited for purposes not only limited to stem cell expansion.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
New Insights Into the Ex Vivo Expansion of Transplantable Human Blood Stem Cells - Technology Networks

Hematopoietic Stem Cells Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cells Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cells Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cells Transplantation (HSCT) sales, revenue and market share for each player covered in this report.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

Synopsis of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

Based onProduct Type, Hematopoietic Stem Cells Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

Autologous Transplant Allogenic Transplant

Based onend users/applications, Hematopoietic Stem Cells Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

Hematopoietic Stem Cells Transplantation (HSCT) Market: Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

The Hematopoietic Stem Cells Transplantation (HSCT) Market Report Can Answer The Following Questions:

What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cells Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cells Transplantation (HSCT)?

Who are the key manufacturers of Hematopoietic Stem Cells Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?

Economic impact on Hematopoietic Stem Cells Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cells Transplantation (HSCT) industry.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cells Transplantation (HSCT)?

What will the Hematopoietic Stem Cells Transplantation (HSCT) Market Size and The Growth Rate be in 2026?

What are the key market trends impacting the growth of the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) Market Challenges to market growth?

What are the types and applications of Hematopoietic Stem Cells Transplantation (HSCT)? What is the market share of each type and application?

What are the key factors driving the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cells Transplantation (HSCT) market?

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post:
Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix...

Post COVID-19 Impact on Cancer Stem Cell Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues.

Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following:

Well help you fight this crisis through our business intelligence solutions.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/32

Pre COVID-19 Analysis on Cancer Stem Cell Market

According to a study by the World Health Organization (WHO), cancer is the cause for every one death out of six occurrences. Growing cases of cancers such as breast cancer, lung cancer and others due to poor diet patterns, air pollution, sexually transmitted infections, alcohol consumption. Other types of cancer are liver cancer, pancreas cancer, brain cancer, bladder cancer, colon, and blood cancer. The most common cures for cancer are chemotherapy, radiation, and surgeries. These procedures have an adverse effect on the human body. High doses of radiation and chemotherapy destroy the blood-forming stem cells. Stem cells are the soft tissues of the bone that grow inside the bone marrow. Stem cell transplants restore the blood-forming stem cells. These stem cells grow into platelets, RBCs, and WBCs that are required by the body to fight illness and provide oxygen. Usually, these transplants are done within the family to find the closest match.

According to a study,Cancer Stem Cells Marketby Research Dive, the global market will surpass $1,722.7 million by 2026. Rising number of cancer patients, coupled with the latest advancements in cancer stem cells will upsurge the global market by the year 2026.

Regional Investment Opportunities:

North America cancer stem cell market is generated revenue of $365.64 million by end of 2018 and is anticipated to rise at 10% CAGR during the analyzed period. Asia-Pacific market registered a growth rate of 11.2% during the forecast period. This market will surpass $367.68 million by 2026, growing from $157.26 million in 2018. China, India, and Japan are the key contributors to the growth of regional market.

Check out How Stem-cell based cancer segment is will generate revenue of $896.9 Mn by the year of 2026. Click here to know more in details @ https://www.researchdive.com/purchase-enquiry/32

Stem Cells for Cancer

Cancer stem cells or CSCs are a subpopulation of cells that has the driving force of carcinogenesis. Characteristics of cancer stem cells are proliferation, and differentiation capabilities and distinctive self-renewal. These characteristics play a vital role in many stages of cancer such as cancer initiation, drug resistance, progression, maintenance, and metastasis or relapse. CSCs have traits that are linked with normal stem cells and are found within hematological cancers or tumors.

Check out How Cancer stem cells market for breast cancer is projected to hold a dominant share, owing to the genetic influences & alcohol use @ https://www.researchdive.com/download-sample/32

Stem Cell-based therapy

According to the World Health Organization (WHO), the most common cause of deaths in women diagnosed with cancer is breast cancer.Global cancer stem cells marketis projected to reach up to $896.9 million by the end of 2026 as the stem cell-based cancer therapy and targeted cancerous stem cell therapy are advancing in the medical field. Cell-based therapy is split into allogenic Stem Cell therapy and autologous Stem Cell therapy. Allogenic Hematopoietic Stem Cell Transplantation is more beneficial than the autologous Hematopoietic Stem Cell Transplantation for Breast cancer based on different aspects such as cancer-free graft & immune-mediated Graft vs Tumor effect mediated by the donors immune cell.

Successful engraftment rates together with lesser transplant-related mortality and the presence of Graft vs Tumor effect made allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity conditioning is the better choice option for the treatment of multiple solid tumors. Due to aforesaid aspects, it is anticipated that allogenic cell therapy will be the rising point for the cancer stem cell market. The global market for stem cell-based cancer therapy is estimated to grow at 9.3% CAGR in 2026 from $440.3 million in 2018.

Advancements in Cancer Stem Cell Transplantation

The prime reason for such huge growth is majorly owed to the rising developments in stem cell therapy of the Asia-Pacific and Europe region. Physicians in Canada are endorsing and promotion of stem cell interventions, which are ethical, legal, and regulatory. U.S. and Canada are leading the cancer stem cell market in the North America region. The North America market is expected to grow over the forecast period and is further projected to generate revenue of $783.8 million by 2026 from its market value of $365.6 million in 2018. While the Asia-Pacific Cancer Stem Cells Market is anticipated to rise to $367.7 Million till 2026 and the Europe Cancer Stem Cells Market is anticipated to generate revenue of $419.5 Million till 2026. Amongst these regions, the Asia-Pacific region is anticipated to be the fastest-growing region for cancer stem cells market. Governing bodies of India, Japan, and other countries are promoting Stem cell transplant by constructing new infrastructure and enlisting new strategies for the launch of centers of stem cells.

The major players in the global cancer stem cell market are introducing several strategies to reinforce their presence in the market

Get Access to Full Report (TOC, Figures, Chart, etc.) @ https://www.researchdive.com/32/cancer-stem-cells-market

Segmentation Growth Definition of Cancer Stem Cells Market:

Breast cancer market will surpass $295.0 million in the year 2026, and is anticipated to rise at 10.4% CAGR during the estimate period. The cancer stem cells market for bladder is anticipated to increase at 11.2% CAGR, and will surpass $275.8 million by 2026, rising from $117.9 million in 2018. Global market for stem cell based cancer therapy was $440.3 million by end of 2018 and is anticipated to grow at 9.3% CAGR. This is majorly due to the rising advancements in stem cell therapy of Asia-Pacific and Europe region.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

See the rest here:
World Health Organization (WHO) says Cancer is the cause for every one death out of six occurrences which makes Cancer Stem Cells Market to create...

A Nottinghamshire girl needs to find a bone marrow donor within weeks as she battles leukaemia for the second time.

Amy Bartlett, 14, of West Bridgford, was described as a playful, happy and energetic girl before her blood cancer diagnosis.

Having spent part of her childhood in New Zealand, she was a water baby representing her school in water polo and loved to be in the pool and sea, taking part in the little nippers surf life-saving programme.

More recently, she enjoyed being a member of West Bridgfords Colts football team.

In 2018, when she was 12, Amy began to complain of feelings of aches in her wrists and ribs and developed a small rash across her tummy and back.

Tests at Nottingham Childrens Hospital later confirmed she had leukaemia - devastating and heartbreaking news for Amy and her family.

Amy showed strength from the get-go, reassuring her parents that she could fight the blood cancer.

"Mummy, it is ok its better I get it, than another smaller child. I am stronger and so have a better chance to beat it," were her first words after the news was broken to her.

Her leukaemia was categorised as high risk, meaning despite her young age, she had to receive the most intensive rounds of chemotherapy administered to children diagnosed with the disease, causing her hair to fall out within just a few days of treatment starting.

Having not had the smoothest ride through her treatment, suffering liver problems, developing steroid induced diabetes and several allergies to medications she was given, Amy soon needed a wheelchair to get in and out of hospital.

Turning the 12-year-olds life upside down, Amy could not go back to school, but tried desperately hard to keep up with her school work.

Counting down the days until the planned end of her therapy on July 4, the entire family were holding onto the light at the end of the tunnel, when the devastating news of a relapse shattered their dreams.

Her mum Marie said: How do you tell your daughter, whose tiny body has been through so much already, that the cancer she has fought so hard to overcome has returned?

"It ripped my heart out to tell her and hold her whilst trying to convince her that she had done it once and she could do it again.

The relapse has meant that Amy has restarted her intensive chemotherapy. The plan is to then proceed to a bone marrow/stem cell transplant, if a suitable donor match can be found.

Amys family say: We need to find a match for Amy ideally within the next two to three weeks, so time is of the essence.

Her brother, Marcus, has been tested but unfortunately he is not a match.

Amys story comes at a time when new donors are needed urgently amidst falling numbers of people signing up to registers, as planned large scale donor recruitment and awareness sessions cannot be run due to Covid-19, but individuals can still request to join the register independently.

Dr Jesky, Amys Consultant at Nottingham University Hospitals, said: For children or adults, like Amy, whose leukaemia has sadly returned, undergoing a stem cell transplant offers the highest chance of a cure.

"Often these donors are volunteers as many patients do not have a suitable family match. Young men are particularly encouraged to register as they are the most frequent chosen donors.

"For the donor the process of donating is simple but for the patient this donation could give them a second chance at life.

NUH is encouraging people to consider signing up to one of the bone marrow registers to increase the chances of finding a potential match for Amy and others who are in similar circumstances. By doing so, you could be the match that saves a life.

There are four main donor registries.

Want us to send you a daily round-up of our biggest stories, and breaking news alerts, direct to your email inbox?

Sign up to our newsletter here.

You only need to register to one as the information from all registers is collated when looking for a match.

1 . The DKMS Registry (age restriction is 18 to 55 years): https://www.dkms.org.uk/en/register-now

2. The Anthony Nolan Registry (age restriction is 16 to 30 years): https://www.anthonynolan.org/8-ways-you-could-save-life/donate-your-stem-cells

3 . The Welsh Bone Marrow Registry (age restriction is 17 to 31 years): https://www.welsh-blood.org.uk/giving-blood/bone-marrow-donor-registry/

4 . The NHS British Bone Marrow Registry (eligibility determined when you attend to give a blood donation): https://www.bbmr.co.uk/joining-the-register/

Follow this link:
Teenager needs a donor within weeks as she battles leukaemia for second time - Nottinghamshire Live

Michael Schumacher is still surviving as he continues to battle complications from the near-fatal head injury he sustained while skiing in 2013. It was reported that the F1 legend is set to undergo another round of stem cell procedure that will help regenerate his nervous system.

Facts about the reported new operation on Schumi

With this surgery, his family and doctors are hoping that he will be able to recover functions in parts of his body. This is because it is aimed at his sensory system that was affected by his injuries.

The Daily Mail reported that currently, Michael Schumacher is being treated and cared for by French cardiologist Dr. Philippe Menasche, a medical expert specializing in stem cell research. It was revealed that a series of surgeries are needed for this treatment, so this is just one of the racing champs operations for his recovery.

In an article that appeared in an Italian publication Le Dauphine, it was reported that Dr. Menasche will do seminal heart surgery on Schumi in his next surgery schedule. It was added that this will take place soon, but the exact date was not revealed.

It is also believed that this will be the second time that the said doctor is operating on Michael Schumacher. The first procedure was said to have been done in September 2019, and Schumi was in the hospital for about three days. At any rate, in this operation, his damaged cells will be replaced with healthy ones that will be taken from his bone marrow.

An experimental stem-cell surgery?

Michael Schumacher has not recovered from his accident that happened more than six years ago. He is currently being treated in his own home in Switzerland, but his exact condition is still a mystery since his family continues to keep everything related to his health a secret.

Dr. Nicola Acciari, a leading neurosurgeon, previously claimed that Michael Schumacher has osteoporosis and suffering from muscle atrophy since he is unable to move for years. The goal is to regenerate Michaels nervous system, The Sun quoted him as saying in connection to the stem cell therapy.

However, Jean-Michel Dcugis, a French journalist, shared to British daily national newspaper, The Times, that the procedure is experimental at this point since Dr. Menasche is actually a cardiologist.

"Our sources say that Michael Schumacher is receiving stem cell perfusions that produce a systemic anti-inflammatory effect, The Sun quoted Dcugis as saying. "It's quite mysterious as Menasch works only on the heart. He is carrying out experiments with secretome that is made by a laboratory from new stem cells and injected into veins, until now only on animals.

Read more:
Michael Schumacher is reportedly getting another stem-cell surgery; Journalist alleged it will be an experimental procedure - EconoTimes

Latest Research Report: Hematology Instruments and Reagents industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Hematology Instruments and Reagents Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Hematology instruments are machines that analyze blood. Used in medical labs, hematology instruments can do blood counts, detect proteins or enzymes, and help to diagnose illnesses or genetic defects.Hematology is the branch of medicine which deals with the study, diagnosis, and treatment of blood-related disorders. It diagnoses issues related to white blood cells, red blood cells, platelets, bone marrow, and lymph nodes. Hematology also deals with the liquid portion of blood known as plasma. Some blood-associated diseases are anemia, leukemia, myelofibrosis, blood transfusion, malignant lymphomas, and bone marrow stem cell transplantation.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/86225

Hematology Instruments and Reagents Market competition by top manufacturers as follow: , Sysmex, Danaher, Nihon Kohden, Siemens, Abbott Laboratories, Boule Diagnostics, HORIBA, Diatron, Drew Scientific, EKF Diagnostics, Mindray, Roche

The risingtechnology in Hematology Instruments and Reagentsmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Hematology InstrumentsHematology Reagents

Market Segment by Applications, covers:Stand-Alone HospitalsCommercial OrganizationsClinical Testing LabsResearch Institutes

The research report summarizes companies from different industries. This Hematology Instruments and Reagents Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Hematology Instruments and Reagents is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/86225

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Hematology-Instruments-and-Reagents-Market-86225

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the article here:
Global Impact of Covid-19 on Hematology Instruments and Reagents Market to Witness Promising Growth Opportunities During 20202026 with Top Leading...

Even though he had Covid-19, Sila Jio Boonklomjit, a five-year-old boy in Thailand, with covid-19 managed to save his sisters life. With the stem cells he donated for her bone marrow transplant.

Doctors only discovered Jio contracted the coronavirus the day before Jintanakan Jean Boonklomjit, his sisters urgent transplant.

Despite the challenges, which included quarantine restrictions placed on Jio on the eve of the transplant procedure. However the treatment was carried out successfully.

And it was done so without Jio passing the coronavirus to Jean.

While the experimental procedure first began in April, the bone marrow was only successfully transplanted on June23 at Ramathibodi Hospital.

Jeans case was believed to be the first successful stem cell transplant from a donor with active Covid-19, according to reports.

She was reported to be in a severe condition as she wasborn with thalassemia a genetic blood disorder that limits the bloods ability to carry oxygen.

There were also difficulties finding a suitable donor for Jean, which left Jio as their best hope, said Suradej Hongeng of the hospitals pediatrics department.

It was a long and uncertain road to this happy outcome, according to the doctor.

Jio and Jean were confirmed to be a genetic match in 2018. The hospital prepared for the transplantation procedure thereafter.

But with any medical procedures, there were certain complications and hurdles involved.

According to Suradej, the siblings young age were part of the difficulties faced during the procedure. Jeans chemotherapy procedure also caused her immune system to be compromised. That delayed the bone marrow transplant until this year.

Still, things turned out well in the end, and the five-year-old boy was applauded for saving his big sisters life.

Its as if my daughter is reborn and gets a new life, said the childrens father, Suchai Boonklomjit.

Jio has since recovered from Covid-19, which was believed to be transmitted from his mother, according to doctors in Thailand.

Thailands health department has reported on Monday that the Kingdom has gone 35 consecutive days without a local Covid-19 Coronavirus case. However health officials have confirmed 7 imported cases with Thai returnees.

The 7 imported covid-19 coronavirus cases brings the total number of infections in Thailand to 3,169 with 58 deaths since January. All the new cases were Thai nationals in quarantine. They recently returning from India and the US to Thailand.

There have been no local transmissions for 35 days Thailands health department said Monday.

Continued here:
Five Year-old Boy with Covid-19 Saves Sisters Life in Thailand - Chiang Rai Times

Summary

A review of 423 patients treated at MSK finds that most people with cancer dont fare any worse if they get COVID-19 than other people who are hospitalized for that infection.

In the early days of the COVID-19 pandemic, many doctors worried that people undergoing treatment for cancer would do particularly poorly if they became infected with the virus that causes the disease. Thats because treatments for cancer, especially chemotherapy, can lower a persons immune defenses and put them at higher risk for all kinds of infections.

But according to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, most people in active cancer treatment dont fare any worse if they get COVID-19 than other people who are hospitalized with the infection. Further research is needed to look at the effects of certain drugs mainly immunotherapies called checkpoint inhibitors, which did seem to make COVID-19 worse. But the researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.

If youre an oncologist and youre trying to figure out whether to give patients chemotherapy, or if youre a patient who needs treatment, these findings should be very reassuring, says infectious disease specialist Ying Taur, one of the studys two senior authors.

Infectious disease expert Ying Taur has cared for many MSK patients who were hospitalized with COVID-19.

The study looked at 423 MSK patients diagnosed with COVID-19 between March 10 and April 7, 2020. Overall, 40% were hospitalized for COVID-19, and 20% developed severe respiratory illness. About 9% had to be placed on a mechanical ventilator, and 12% died. The investigators found that patients taking immunotherapy drugs called immune checkpoint inhibitors were more likely to develop severe disease and require hospitalization. But other cancer treatments, including chemotherapy and surgery, did not contribute to worse outcomes.

The big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.

Factors that did make COVID-19 worse were the same as those seen in studies of people who didnt have cancer. We found that being older, as well as preexisting conditions like heart disease and diabetes, are all drivers of severe COVID-19 illness, says MSK Chief Medical Epidemiologist Mini Kamboj, the studys other senior author. This wasnt surprisingbecause these connections are well established.

Although the study wasnt large enough to make determinations about every treatment and every cancer type, patterns did emerge. Dr. Taur says there was initially great concern about people receiving high doses of chemotherapy for leukemia, especially those who had recently undergone bone marrow or stem cell transplants. Thats because transplants require a persons entire immune system to be wiped out with chemotherapy before they receive new blood cells, leaving them susceptible to all kinds of infections.

Surprisingly, though, Dr. Taur cared for recent transplant recipients who were infected with COVID-19 but didnt have any symptoms. If you think about it more, it makes sense, he says. Most of the complications seen in people with COVID-19 seem to be caused by the bodys immune response to the virus.

On the other hand, immunotherapy drugs called checkpoint inhibitors work by freeing up the immune system to attack cancer. Patients receiving these agents may develop a more robust reaction to the virus that causes COVID-19. This may explain why this study observed higher rates of complications in people with COVID-19 infection who were treated with checkpoint inhibitors.

Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them, Dr. Kamboj says. Its just important for doctors to be extra vigilant about testing and monitoring for the virus and for people with cancer to take extra precautions to avoid infection.

A study published in May 2020 by MSK immunotherapy expert Matthew Hellmann focused exclusively on people with lung cancer who got COVID-19. The researchers didnt find the same risks from immune checkpoint drugs as this Nature Medicine study. More research in this area is needed.

Dr. Kamboj notes that one aspect of this research that sets it apart from other studies is that it included at least 30 days of follow-up after a COVID-19 diagnosis. Also, it reported severe respiratory illness as a main outcome rather than death.

Having that follow-up time is something that a lot of other studies have not included because everyone is in a rush to get their data out. In addition, reporting death rates can overestimate infection-related mortality, especially in the early phase of an epidemic, Dr. Kamboj says. Also, the clinical spectrum and course of this disease is still not fully understood, especially in people with cancer. We wanted to give patients enough time to recover and make sure they didnt need to be readmitted to the hospital.

Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them.

She adds that another strength of the study is that patient outcomes were not affected by constraints caused by a lack of space or supplies even though MSK is in the heart of the COVID-19 epicenter in New York City, where other hospitals faced overcrowding and other issues. This gave researchers a true picture of how cancer patients fare with COVID-19. We saw a surge during the peak of the epidemic in New York, but everyone got the care they needed, Dr. Kamboj explains. We had enough ventilators for everyone who needed them. We never had to make decisions about who to admit to intensive care because of a lack of critical equipment.

Drs. Taur and Kamboj agree that this is just one of many studies that will need to be done on the connections between cancer and COVID-19. We still need to find out more. We need to look at the connections between COVID-19 and particular types of cancer as well as outcomes related to specific chemotherapy drugs, Dr. Taur concludes. But the big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.

See more here:
Should You Delay Cancer Treatment Because of COVID-19? Study Says Most Treatments Dont Worsen Coronavirus Infection - On Cancer - Memorial Sloan...

NantKwest (NASDAQ:NK) has been one of my best investments over the past year and looks to be ready to move higher following another positive data for cancer and development of a COVID-19 vaccine. Recently, the company's CEO, Dr. Patrick Soon-Shiong "PSS", has been on some news segments discussing some of their fresh cancer readouts and the company's potential to develop a premier COVID-19 vaccine. It looks as if their activated NK cell platform is able to be implemented in multiple disciplines of medicine and could be a vital component in future therapeutics. With the share price rising roughly 1000% since my first buy, I have to make some decisions about how I intend to manage my NK position in the coming days, weeks, months, and years. One wrong move and I could miss the chance to bank some profits or possibly sell too early and miss out on future growth.

First, I will take a look at the recent pipeline updates and data. Second, I will discuss why I am so bullish after the recent offering. Finally, I intend to discuss my course of action that will alleviate both of my concerns.

Out of all of NantKwest's clinical-stage engineered natural killer cell programs, I have been waiting to see some data from their first-in-class PD-L1 t-haNK candidate. The company's PD-L1 t-haNK is created using a haNK cell that has PD-L1 CAR, which will provide an innovative method for targeting PD-L1 tumors. NantKwest recently revealed some positive data for in-vivo models of 15 solid tumors in treatment-refractory cancer types and demonstrated activity in the hypoxic environment.

This is significant because healthy donor NK cells are typically impaired in hypoxic environments, so NantKwest's proprietary off-the-shelf NK cells have an advantage over our own NK cells and potentially other NK therapies. Essentially, NantKwest's NK cells are able to work in a tumor environment that typically disables or nullifies our own NK cells' ability to attack the tumor. In addition, the PD-L1 t-haNK cells were able to show some efficacy in infamously treatment-refractory cancers such as triple-negative breast cancer, lung, and urogenital cancer. PSS believes that their highly targeted NK cell therapies have the potential to take on these highly resistant tumors that have "stem-like" cells, which can be impervious to chemotherapy and checkpoint therapies. In fact, the company reported their first patient with advanced metastatic pancreatic cancer treated with PD-L1 t-haNK has revealed a durable complete response.

Not only am I impressed with the company's ability to create one of these Checkpoint CAR-NK-like cells, but the fact the therapy was able to produce a durable complete response in an advanced metastatic pancreatic cancer patient has turned me into a perma-bull. It looks as if PSS has essentially fused the immunotherapy and cell therapy to create a cutting-edge cancer therapeutic. Once again, PSS and NantKwest have revealed a candidate that could define the next generation of oncology therapeutics.

NantKwest and ImmunityBio are working in collaboration on vaccines and therapeutics to fight COVID-19. ImmunityBio will be working on the development of a vaccine and natural killer cell activation, with their immunomodulators. NantKwest will be focusing on their off-the-shelf, cell-based therapeutics to develop therapeutics for COVID-19. It appears that the goal is to develop a broad array of products to prevent and treat various stages of infection or tissue damage.

So far, ImmunityBio and NantKwest have developed "immunomodulator regimens" for COVID-19 for mild, moderate, severe, and critically ill state (Figure 1). In the early-moderate stage of the disease, the two companies are planning on a clinical trial of ImmunityBio's Il-15 'superagonist' N-803. In addition, they are planning another trial using NantKwest's haNK cell, or haNK in combination with convalescent plasma. In the severely ill, the company is looking to employ bone marrow-derived allogeneic mesenchymal stem cells "BM-Allo-MSC" to diminish the "cytokine storm". These cells can be grown in ImmunityBio's automated GMP-in-a-Box in roughly 7-9 days, which could allow providers to create these therapeutics in-house and essentially on-demand. NantKwest has filed an IND and anticipates beginning trials in the near future.

Figure 1: NantWorks COVID-19 Programs (Source: NantKwest)

In terms of a vaccine, ImmunityBio has a second-generation Ad5 platform that will produce a vector that is immunologically "quiet" and could allow patients who were previously vaccinated with an Ad5 vaccine. In addition, ImmunityBio's vaccine goes after both the spike "S" protein and the nucleocapsid "N" protein in order to induce antigen-specific T-cell immunity. This is significant because it is the only known COVID-19 vaccine that is targeting both, which could allow an extended immunity to the virus compared to vaccines which are only targeting the spike proteins. What is more, this Ad5 platform has demonstrated humoral and cell-mediated immunity for several other deadly viruses such as H1N1, HIV, Chikungunya, and Zika. Therefore, we should expect ImmunityBio's vaccine to show some efficacy against COVID-19 and perhaps be the premier vaccine.

Once COVID-19 hit the United States and the healthcare industry started pumping out vaccines and therapeutics, I almost instantly thought "when is Patrick Soon-Shiong going to unveil his COVID-19 solution?" NantWorks has repeatedly produced some extremely impressive product candidates for just about every major issue in healthcare. The minute the company released their press release revealing their candidates, I was looking for the market to have an immediate response both in share price and an increase in chatter. Unfortunately, it appears as if the NantWorks structure has once again caused some confusion, and the response was quite mute compared to other COVID-19 plays. It is possible that NantKwest has a therapy that can target the virus with minimal safety concerns. Is the market missing NantKwest again? Once again, it looks as if ImmunityBio has some of the primary cogwheels that are required for their COVID-19 programs, and NantKwest is just a minor player with very little to claim in the end.

Indeed, NantKwest and their NK cells appear to have a critical role in many of the NantWorks programs. However, I didn't feel reassured in the recent COVID-19 press releases. In fact, I felt as if PSS was using NantKwest's IR as a vehicle to get ImmunityBio's (a private NantWorks company) pipeline some public exposure. As a result, I would like to see some more details about NantKwest's involvement in these collaboration programs.

Back on June 24th, NantKwest announced that they intended to execute a public offering with Piper Sandler & Co., for 7.41M shares of common stock at $9.50 per share, with Piper Sandler & Co. purchasing 3.7M at $8.93 per share. What is more, PSS agreed to purchase 3.71M shares at $12.12 per share. The net proceeds are anticipated to be around $76.4M, which will be added to roughly $17M in cash and cash equivalents the company had at the end of Q1.

Typically, I am not incredibly excited about a public offering due to a negative reaction in the share price and shareholder dilution. However, I am now very bullish following the recent offering as a result of PSS willing to purchase shares at market value. It is often quite bullish to see insiders buying common stock, but it isn't common to see insiders looking buy at 52-week highs. Now, I am looking to join PSS and average up in the coming days or weeks once the technical analysis gives me the green light, and the recent volatility in the market subsides.

Admittedly, I decided to reduce my position during the January spike, but I was willing to reapply those profits once the stock was able to break out of its downtrend and cross above 200-day EMA (Green Circle on Figure 22). Now, I am waiting to see where the market is going to NK in the coming days before adding to the position. I am keeping an eye on several indicators and trend line to give me the signal to click the buy button.

Figure 2: NK Daily (Source: Trendspider)

Looking at the daily chart, we can see the stock had no problem busting through its previous 52-week high. However, the chart shows a double-top with two inside bars and an abrupt sell-off coming after the offering news. The combination of a strong bullish move followed by a negative news event will make this addition a bit tricky. I am going to wait and see if the share price is able to bounce off the red uptrend line and bust through the recent green downtrend line. Once the stock makes a decision, I am going to turn to the RSI to see if the share price remains above the green trend line and is still trading above $8.40 per share. If these conditions line up, I will make a small addition to my NK position in anticipation the stock will make another leg higher. If the share price breaks down and the RSI trend is broken, I will sell roughly half of my position and wait to see if the stock wants to retest the 200-day EMA before considering an addition.

I expect to make a few more small additions to my NK position over the course of 2020 and will leave the year with a respectable position. However, I am not going to "go-all-in" until I figure out how NantKwest will ultimately land in the NantWorks hierarchy.

Disclosure: I am/we are long NK. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the original here:
NantKwest: The Market And The Government Are Missing Out On This Blockbuster - Seeking Alpha

By: Lifestyle Desk | New Delhi | Updated: June 27, 2020 12:09:31 pm Heres everything to know about the blood disorder. (Source: Getty Images/Thinkstock)

Sickle cell disease (SCD) is an inherited group of blood disorder which is genetic in nature. It is usually transferred from parents to the child during birth i.e. both the parents can be carries of SCD. Healthy RBCs are round in shape, which moves through small blood vessels and carries oxygen to all parts of the body. In someone who has SCD, the RBC becomes sticky and hard and start to look like C- shaped similar to that of a farm tool sickle. The sickle cells die early, which causes a constant shortage of RBC, which leads to low oxygen carriers in the body, mentioned Dr Rahul Bhargava, director and head, haematology and bone marrow transplant, Fortis Memorial Research Institute, Gurugram. Also, when sickle cells travels they tend to get stuck in small blood vessels and restrict the blood flow. This can cause pain in the joints, chest and other serious problems such as stroke, acute chest syndrome and infections.

Anaemia

SCD can lead to shortage of RBC which makes the patient anaemic. It can lead to less oxygen supply in the body causing fatigue.

Episodes of pain. SCD patients suffer from episodes of periodic pain. Sickle-shaped blood cells can block the flow of blood which in tiny vessels of abdomen, chest and joints, thus leading to pain.

Feet and hands swelling

Sickle-shaped RBC can block then flow of blood which can cause swelling in the hands and feet.

Frequent infections

Sickle cells can damage the spleen and make the person vulnerable to diseases and infections. Vaccination is usually prescribed in childhood to keep infections at bay.

Delayed growth or puberty

RBC is the carrier of oxygen and other nutrients. With low RBC, there is no enough oxygen in the body which can slow the growth in infants and children which leads to delayed puberty in children.

Vision problems

Vision is affected when the flow of blood is affected.

SCD can lead to a lot of complication, including Stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers and more such complications.

SCD can be diagnosed with a simple blood test. Parents are advised to get the screening done before conceiving as it is transmitted from parents. For newborns, the test is done in the hospitals as a routine screening. There is no single treatment for SCD patients and it varies from patient to patient on the basis the symptoms. Before starting any medication, consult a haematologist who specialises in blood disorders.

The only cure for SCD is getting a bone marrow transplant (BMT), which is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Stem cells are easily taken from the donor and planted in the recipient. After the BMT procedure, the patient can lead a healthy and normal life.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the rest here:
Sickle Cell Disease: All you need to know - The Indian Express

Dana-Farber Patient Recovering Well After Cancer and the Coronavirus

Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.

None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.

When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.

A Blood Cancer Diagnosis

In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.

Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.

In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.

The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.

This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.

Follow this link:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News

Post COVID-19 Impact on Cancer Stem Cell Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues.

Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following:

Well help you fight this crisis through our business intelligence solutions.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/32

Pre COVID-19 Analysis on Cancer Stem Cell Market

According to a study by the World Health Organization (WHO), cancer is the cause for every one death out of six occurrences. Growing cases of cancers such as breast cancer, lung cancer and others due to poor diet patterns, air pollution, sexually transmitted infections, alcohol consumption. Other types of cancer are liver cancer, pancreas cancer, brain cancer, bladder cancer, colon, and blood cancer. The most common cures for cancer are chemotherapy, radiation, and surgeries. These procedures have an adverse effect on the human body. High doses of radiation and chemotherapy destroy the blood-forming stem cells. Stem cells are the soft tissues of the bone that grow inside the bone marrow. Stem cell transplants restore the blood-forming stem cells. These stem cells grow into platelets, RBCs, and WBCs that are required by the body to fight illness and provide oxygen. Usually, these transplants are done within the family to find the closest match.

Check out How Stem-cell based cancer segment is will generate revenue of $896.9 Mn by the year of 2026. Click here to know more in details @ https://www.researchdive.com/purchase-enquiry/32

According to a study,Cancer Stem Cells Marketby Research Dive, the global market will surpass $1,722.7 million by 2026. Rising number of cancer patients, coupled with the latest advancements in cancer stem cells will upsurge the global market by the year 2026.

Cancer Stem Cells Market Segmentation by Cancer Form

Regional Investment Opportunities:

North America cancer stem cell market is generated revenue of $365.64 million by end of 2018 and is anticipated to rise at 10% CAGR during the analyzed period. Asia-Pacific market registered a growth rate of 11.2% during the forecast period. This market will surpass $367.68 million by 2026, growing from $157.26 million in 2018. China, India, and Japan are the key contributors to the growth of regional market.

Cancer Stem Cells Market Segmentation by Application

Stem Cells for Cancer

Cancer stem cells or CSCs are a subpopulation of cells that has the driving force of carcinogenesis. Characteristics of cancer stem cells are proliferation, and differentiation capabilities and distinctive self-renewal. These characteristics play a vital role in many stages of cancer such as cancer initiation, drug resistance, progression, maintenance, and metastasis or relapse. CSCs have traits that are linked with normal stem cells and are found within hematological cancers or tumors.

Check out How Cancer stem cells market for breast cancer is projected to hold a dominant share, owing to the genetic influences & alcohol use @ https://www.researchdive.com/download-sample/32

Stem Cell-based therapy

According to the World Health Organization (WHO), the most common cause of deaths in women diagnosed with cancer is breast cancer.Global cancer stem cells marketis projected to reach up to $896.9 million by the end of 2026 as the stem cell-based cancer therapy and targeted cancerous stem cell therapy are advancing in the medical field. Cell-based therapy is split into allogenic Stem Cell therapy and autologous Stem Cell therapy. Allogenic Hematopoietic Stem Cell Transplantation is more beneficial than the autologous Hematopoietic Stem Cell Transplantation for Breast cancer based on different aspects such as cancer-free graft & immune-mediated Graft vs Tumor effect mediated by the donors immune cell.

Successful engraftment rates together with lesser transplant-related mortality and the presence of Graft vs Tumor effect made allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity conditioning is the better choice option for the treatment of multiple solid tumors. Due to aforesaid aspects, it is anticipated that allogenic cell therapy will be the rising point for the cancer stem cell market. The global market for stem cell-based cancer therapy is estimated to grow at 9.3% CAGR in 2026 from $440.3 million in 2018.

Advancements in Cancer Stem Cell Transplantation

The prime reason for such huge growth is majorly owed to the rising developments in stem cell therapy of the Asia-Pacific and Europe region. Physicians in Canada are endorsing and promotion of stem cell interventions, which are ethical, legal, and regulatory. U.S. and Canada are leading the cancer stem cell market in the North America region. The North America market is expected to grow over the forecast period and is further projected to generate revenue of $783.8 million by 2026 from its market value of $365.6 million in 2018. While the Asia-Pacific Cancer Stem Cells Market is anticipated to rise to $367.7 Million till 2026 and the Europe Cancer Stem Cells Market is anticipated to generate revenue of $419.5 Million till 2026. Amongst these regions, the Asia-Pacific region is anticipated to be the fastest-growing region for cancer stem cells market. Governing bodies of India, Japan, and other countries are promoting Stem cell transplant by constructing new infrastructure and enlisting new strategies for the launch of centers of stem cells.

The major players in the global cancer stem cell market are introducing several strategies to reinforce their presence in the market

Get Access to Full Report (TOC, Figures, Chart, etc.) @ https://www.researchdive.com/32/cancer-stem-cells-market

Segmentation Growth Definition of Cancer Stem Cells Market:

Breast cancer market will surpass $295.0 million in the year 2026, and is anticipated to rise at 10.4% CAGR during the estimate period. The cancer stem cells market for bladder is anticipated to increase at 11.2% CAGR, and will surpass $275.8 million by 2026, rising from $117.9 million in 2018. Global market for stem cell based cancer therapy was $440.3 million by end of 2018 and is anticipated to grow at 9.3% CAGR. This is majorly due to the rising advancements in stem cell therapy of Asia-Pacific and Europe region.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

Originally posted here:
Global cancer stem cells market is projected to reach up to $896.9 million by the end of 2026 - Cole of Duty

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105[emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

View original post here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

The research report by The Insight Partners, titled, Cell Therapy Market, offers a comprehensive analysis of key growth drivers, key segments, development strategies, market opportunities, and competitive landscape. This study offers detailed insights for market players, investors, stakeholders, and new entrants to understand the industry dynamics and determine strategic steps to gain a competitive advantage.

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00009666/

Major Players Included in this report are as follows

Kolon TissueGene, Inc. MEDIPOST JCR Pharmaceuticals Co. Ltd. Stemedica Cell Technologies, Inc. Osiris Therapeutics, Inc. NuVasive, Inc. Fibrocell Science, Inc. Vericel Corporation Cells for Cells Celgene Corporation

Cell Therapy Market: Regional analysis includes:

This report on Cell Therapy Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Cell Therapy Market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters. The study is ubiquitous of the major insights related to the regional spectrum of this vertical as well as the companies that have effectively gained a commendable status in the Cell Therapy Market.

The global cell therapy market is segmented on the basis of therapy type, product, technology, application, end user. Based on the therapy type the market is classified as autologous, and allogeneic. Based on product the market is segmented as equipment, consumables, software and services. Based on technology the market is segmented as somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Based on application the market is classified as oncology, cardiology, orthopedic, wound management and others. And based on end user the market is divided into hospitals, regenerative medicine centers, and research institutes.

The Cell Therapy Market research covers an exhaustive analysis of the following data:

Historical and future growth of the global Cell Therapy Market.

Segmentation of the Cell Therapy Market to highlight the growth prospects and trends impacting these segments.

Changing consumption behavior of customers across various regions.

Regional analysis on the basis of market share, growth outlook, and key countries.

Agreements, product launches, acquisitions, and R&D projects of different Cell Therapy Market players.

The Cell Therapy Market research addresses critical questions, such as

Why is region surpassing region in terms of value by the end of 2027?

How are the consumers using Embolization Devices for various purposes?

Which players are entering into collaborations in the market of the Embolization Devices?

At what rate has the global Cell Therapy Market been growing throughout the historic period?

In terms of value, which segment holds the largest share?

Purchase Copy of This Report at:https://www.theinsightpartners.com/buy/TIPRE00009666/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email:[emailprotected]

Follow this link:
Cell Therapy Market Top Manufacturers, Industry Size, Challenges, Drivers, Countries, And Technology Forecast To 2027 | Stemedica Cell Technologies,...

The frenetic search for the miracle that will rid the world of COVID-19 is branching out in a thousand directions, and a large part of the microbial treasure hunt is going on in the Bay Area, where major progress has been made in the 100 days since residents were ordered to shelter in place.

Scientists at universities, laboratories, biotechnology companies and drug manufacturers are combing through blood plasma taken from infected patients for secrets that will help them fight the disease.

The key is likely a super-strength antibody found in some patients. But researchers must first figure out how those antibodies work and how they can be harnessed and used to stop the many health problems associated with COVID-19, particularly acute respiratory distress syndrome, or ARDS, which has killed more people than any other complication connected to the disease.

Other developments showing promise include injections of mesenchymal stem cells, found in bone marrow and umbilical cords, that doctors are studying to battle inflammation caused by ARDS. And a steroid called dexamethasone reduced the number of deaths by halting the overreactive immune responses in seriously ill patients in the United Kingdom.

In all, more than 130 vaccines and 220 treatments are being tested worldwide.

What follows is a list of some of the most promising elixirs, medications and vaccines with ties to the Bay Area:

Monoclonal antibodies / Vir Biotechnology, San Francisco: Scientists at Vir and several institutions, including Stanford and UCSF, are studying monoclonal antibodies, which are clones of coronavirus-fighting antibodies produced by COVID-19 patients.

The idea is to utilize these neutralizing antibodies which bind to the virus crown-like spikes and prevent them from entering and hijacking human cells.

Only about 5% of coronavirus patients have these super-strength antibodies, and those people are believed to be immune to a second attack.

The trick for scientists at Vir is to identify these neutralizing antibodies, harvest, purify and clone them. If they succeed, the resulting monoclones could then be used to inoculate people and it is hoped give them long-term immunity against the coronavirus. The company recently signed a deal with Samsung Biologics, in South Korea, to scale up production of a temporary vaccine in the fall after clinical trials are complete.

Another monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn. The companys chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Interferon-lambda / Stanford University: Doctors at Stanford are running a trial to see if interferon-lambda, which is administered by injection, helps patients in the early stages of COVID-19. Interferon-lambda is a manufactured version of a naturally occurring protein that has been used to treat hepatitis. Stanford doctors hope it will boost the immune system response to coronavirus infections.

Dr. Upinder Singh, a Stanford infectious-disease expert, said the trial has enrolled more than 50 patients and is halfway finished. We have noted that patients tolerate the drug very well, she said.

Mesenchymal stem cells / UCSF and UC Davis Medical Center: UCSF Dr. Michael Matthay is leading a study about whether a kind of stem cell found in bone marrow can help patients with ARDS. Matthay hopes that the stem cells can help reduce the inflammation associated with some of ARDS most dire respiratory symptoms, and help patients lungs to recover.

Matthay is aiming to enroll 120 patients in San Francisco, the UC Davis Medical Center in Sacramento and hospitals in a handful of other states. He said the trial, which includes a small number ARDS patients who dont have COVID-19, should have results within a year. So far 17 patients are enrolled in the trial, most of them in San Francisco.

Remdesivir / Gilead Sciences (Foster City): Remdesivir, once conceived as a potential treatment for ebola, was the first drug to show some promise in treating COVID-19 patients. The drug interferes with the process through which the virus replicates itself. A large study led by the federal government generated excitement in late April when officials said hospitalized patients who received remdesivir intravenously recovered faster than those who received a placebo.

A later study looking at dosage showed some benefit for moderately ill COVID-19 patients who received remdesivir for five days, but improvement among those who got it for 10 days was not statistically significant. Gilead, a drug company, recently announced that it will soon launch another clinical trial to see how remdesivir works on 50 pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. More than 30 locations in the U.S. and Europe will be involved in the trial, the company said.

Coronavirus crisis: 100 days

Editors note: Its been 100 days since the Bay Area sheltered in place, protecting itself from the coronavirus pandemic. What have we learned in that time? And what does the future hold for the region and its fight against COVID-19? The Chronicle explores the past 100 days and looks to the future in this exclusive report.

Favipiravir / Fujifilm Toyama Chemical (Stanford University): This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a Stanford University trial that began this month. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

Stanford epidemiologists want to see if favipiravir, which has shown promising results in other trials, prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. The Stanford study, the only outpatient trial for this drug in the nation, is enrolling 120 people who have been diagnosed with COVID-19 within the past 72 hours. Half of them will get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Colchicine / UCSF (San Francisco and New York): The anti-inflammatory drug commonly used to treat gout flare-ups is being studied in the U.S. by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the bodys production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19. About 6,000 patients are receiving colchicine or a placebo during the clinical trial, dubbed Colcorona, which began in March and is expected to be completed in September.

Selinexor / Kaiser Permanente: Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing, as a potential COVID-19 treatment. The drug has both antiviral and anti-inflammatory properties, and its administered orally, according to Kaisers Dr. Jacek Skarbinski. The trial aims to enroll 250 patients with severe symptoms at Kaiser and other hospitals that are participating nationwide.

VXA-COV2-1 / Vaxart, South San Francisco: The biotechnology company Vaxart is testing this drug to see if it is as effective at controlling COVID-19 as trials have shown it to be against influenza. VXA-COV2-1, the only potential vaccine in pill form, uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

Its the only vaccine (candidate) that activates the first line of defense, which is the mucosa, said Andrei Floroiu, Vaxarts chief executive, noting that intravenous vaccines kill the virus after it is inside the body. Our vaccine may prevent you from getting infected at all.

The drug was effective against influenza and norovirus in trials and appears to work on laboratory animals, Floroiu said. He expects trials of VXA-COV2-1 on humans to begin later this summer.

VaxiPatch / Verndari (Napa and UC Davis Medical Center): Napa vaccine company Verndari makes a patented adhesive patch that can deliver a vaccine instead of a shot. Now, the company is trying to make a vaccine for COVID-19 that they can administer through that patch. At UC Davis Medical Center in Sacramento, Verndari researchers are developing a potential vaccine that relies on the coronavirus spike-shaped protein. When injected into a person, the substance would ideally train their body to recognize the virus and fight it off without becoming ill.

A spokeswoman told The Chronicle that the companys preclinical tests have shown early, positive data in developing an immune response. Verndari hopes to move into the next phase of testing in the coming weeks and start clinical trials in humans this year.

If the vaccine is proved effective and safe, patients could receive it through the mail, according to company CEO Dr. Daniel Henderson. The patch would leave a temporary mark on the skin that patients could photograph and send to their doctor as proof they have taken the vaccine, Henderson has said.

Peter Fimrite and J.D. Morris are San Francisco Chronicle staff writers. Email: pfimrite@sfchronicle.com, jd.morris@sfchronicle.com Twitter: @pfimrite, @thejdmorris

Go here to read the rest:
Efforts at coronavirus vaccines and treatments abound in the Bay Area - San Francisco Chronicle

Whoever would have thought that the turn of a new decade would bring such a cataclysmic event to our world? Our economy was humming along. Times were good, and business was booming. Then along comes a pestilence in the form of a microscopic virus that has shaken our world to its core.

Tens of thousands of Americans have died. Hundreds of thousands have become ill. Millions have lost their jobs. And tens of millions have been isolated and socially distanced from friends and loved ones. History will look back on the Covid-19 pandemic as a turning point in our lives.

And while all of this has been going on, manufacturers continue to produce goods, warehouses process orders, trucks roll and deliver, and supply chains continue to function.

It has not been without a hitch, but supply chain has certainly been among the few bright spots during the pandemic. Finally, every American is aware of what supply chain professionals do each and every day without fanfare. Warehouse workers and drivers continue to show up for work, risking their health and their emotional well-being to keep freight moving.

In the following stories, we salute some of the many individuals and companies who have used their talents and resources to bring healing and hope, deliver comfort, and save lives during the Covid-19 crisis. We thank these unsung heroes who have quietly gone about their work to make sure the rest of us have what we need to make life appear almost normal.

Click one of the headlines below to skip ahead to a particular story.

Back to index

Stepping up their use of technology is one of the many ways logistics firms are meeting volatile business conditions brought on by the Covid-19 pandemic. Fort Wayne, Indiana-based Circle Logistics and White Plains, New York-based Capital Logistics are two examples of companies digging deeper into visibility tools to help monitor and manage freight shipments, especially for critical food and medical supply chains.

Both companies said this spring they were using Descartes Systems Groups MacroPoint real-time freight visibility solution to track critical loads for customers such as the Federal Emergency Management Agency (FEMA) and major grocery brands. Circle Logistics said it shifted its entire transportation network to manage a 700% increase in volume from customers moving critical freight, including personal protective equipment (PPE), respirators, cots for FEMA, and grocery loads. Company leaders said the platform allows it to better track the movement of goods under volatile conditions.

At Capital Logistics, leaders are also integrating Descartes Aljex cloud-based transportation management system (TMS) to manage volatility. Designed for freight brokers, the system automates planning, freight tendering, and dispatching as well as back-office functions including accounting, invoicing, and reporting. The integration with MacroPoint provides real-time freight visibility to automatically track loads, greatly reducing the manual efforts for track-and-trace teams, according to Descartes.

As our customers focus on keeping food supply chains functioning, having real-time visibility into the status of critical freight has increased our ability to keep pace with the unpredictable demand grocery stores are experiencing, Greg Ackner, vice president at Capital Logistics, said in late April. In one case, we went from moving two to three truckloads of milk per week to distribution centers serving multiple states to 50 to 60 truckloads per week.

Back to index

Forklift vendor Combilift is stepping up to address the shortage of medical equipment for treating Covid-19 patients by developing a splitter device that turns one ventilator into multiple ventilation stations.

Monaghan, Ireland-based Combilift used its resources in engineering and software design to pivot from the material handling sector to create the Combi-Ventilate, saying the unit will address the requirements of medical professionals in the Covid-19 emergency.

The Combi-Ventilate uses standard pipes and fittings for easy assembly, offers individual patient filters that prevent cross contamination, and supports dedicated computer screens for each patients vital information. The device is designed as an attachment that can be added to any brand of ventilator, installed easily into a hospitals intensive care unit (ICU), and purchased for a fraction of the cost of a standard ventilator, the firm said.

Back to index

The International Foodservice Distributors Association (IFDA) and FMI-Food Industry Association are partnering to help keep store shelves stocked amid the coronavirus pandemic. In March, the groups announced a partnership that aims to match food-service distribution companies that have excess product, warehouse space, and transportation capacity with food retailers and wholesalers in need of assistance, the associations said.

The partnership addresses the issue of excess product and capacity caused by the closing of restaurants, schools, and other businesses with retailers and wholesalers seeking to replenish store shelves more quickly. IFDA and FMI are gathering information from their members and matching capacity to need geographically, essentially functioning as a clearinghouse for contact information, according to IFDA spokeswoman Meghan Cieslak. She emphasized that the program aims to help fill demand for products but will also help fill demand for trucks, drivers, warehouse staff, warehouse storage, and similar needs.

Back to index

The Illinois-based material handling equipment dealer MH Equipment has used its corporate charity program to support several initiatives during the economic shutdowns and shortages caused by the Covid-19 pandemic.

First, the firm launched a campaign to address food shortages faced by community food banks and pantries during the coronavirus emergency. The companys Purpose Unites program allows employees to automatically deduct part of their paychecks to support local food banks. Along with donations from the companys His First Foundation charitable program, the effort raised nearly $187,000 across 33 office locations in just four days.

Second, the companys charity arm paid many of MH Equipments own employees to perform volunteer community service, using spare time they had available due to a drop in demand during the recession. MH Equipment compensated them for more than 4,000 hours of volunteer community service time across several Midwest states throughout the month of April. Those tasks included helping food banks with loading/unloading trucks, meal delivery, and packaging; making masks; mowing yards for the elderly and for nonprofit organizations; and using their technical skills to assist with light mechanical work on fire engines at volunteer fire departments.

Back to index

Truck drivers moving in and out of hot zones to perform essential work are receiving personal protective equipment (PPE) thanks to a collaboration between DDC FPO, a back-office partner for the transportation industry, and Truckers Emergency Assistance Responders (TEAR), a 501c3 nonprofit organization founded with the mission to help truck drivers in distress.

TEAR has built and deployed a network of corporate sponsors and volunteers to source, assemble, and distribute PPE kits to truck drivers on the front lines. Delivered at truck stops and rest areas, each PPE kit includes masks, hand sanitizer, gloves, antiseptic wipes, and snacks. The drivers are so appreciative, TEAR leader Desiree Wood said. They spend all day by themselves and arent used to receiving anything for free, let alone being recognized. They are thrilled to receive the kits.

Back to index

Supply chain technology provider Trimble Inc. has launched a free web app that displays truck-stop status and amenity information, allowing truck drivers to find essential break locations, showers, and restaurants.

The information comes as many break locations have closed completely or have shuttered certain amenities during the coronavirus crisis. Currently available on desktop or mobile devices in North America only, the Covid-19 Safe Haven Web App is intended to help the transportation community find out which locations are closed and which conveniences are open. Drivers can also use the platform to find Walmart locations with overnight parking, view live traffic and weather reports, and help their peers by reporting location closings.

Back to index

E-commerce retailer Amazon.com Inc. has teamed up with medical device manufacturer Boston Scientific to deliver donated face shields to health-care facilities around the U.S. fighting the Covid-19 pandemic.

Health-care volunteer coalition GetUsPPE organized the effort, under which Boston Scientific mobilized employees at a dozen sites to produce and donate the personal protective equipment (PPE), while Amazon offered logistics support. Amazon provided space on its trailers to deliver the shields from Boston Scientific to local delivery stations, where Amazon associates have worked with delivery service partners in Chicago, Detroit, and the Washington, D.C./Baltimore metro areas to deliver the face shields to hospitals and clinics.

Back to index

Job training nonprofit group Goodwill of South Florida has converted a portion of its sewing operations to manufacture 20,000 masks for employees at transportation and logistics company Ryder System Inc. The initiative extends a long relationship between the two organizations, since company founder James Ryder was also one of three founders of Goodwill some 60 years ago, David Landsberg, CEO of Goodwill of South Florida, said in a release.

The masks are being used to protect Ryders essential employees as they support the flow of goods and services needed in the fight against Covid-19. Each mask is made with camouflage material on the outside, a softer fabric on the inside, and elastic ear loops.

Back to index

Automaker Kia Motors America is donating personal protective equipment (PPE) to hospitals and medical facilities during the Covid-19 crisis. The face shields are assembled at its Kia Motors Manufacturing Georgia plant in West Point, Georgia, and the brand plans on donating a total of 300,000 face shields nationwide.

A group of company volunteers called Telluriders recently delivered face shields to Morristown Medical Center/Atlantic Health in Morristown, New Jersey. The deliveries were part of Kias Accelerate the Good initiative, which includes ongoing face shield donations to medical facilities in New Jersey, Southern California, and Georgia.

Back to index

Beer maker Sierra Nevada Brewing has donated some of its food laboratory resources in Chico, California, to making a critical component used in tests for detecting Covid-19 infections.

Sierra Nevada is using its quality assurance labusually dedicated to testing beer for unwanted bacteria and wild yeastfor creating the viral transport medium that is in short supply for enabling coronavirus tests. The medium is used to protect the swab that doctors insert into patients nostrils while it is transferred to a medical lab. In this case, the beer maker has already delivered 1,000 vials of the liquid to Californias Enloe Medical Center and is planning to make up to 10,000 more.

Back to index

Employees at Jacksonville, Florida-based third-party logistics service provider (3PL) Atlantic Logistics have started a bulk hand sanitizer rebottling program that will serve local truck drivers. In April, employees partnered with TravelCenters and TA-Petro to set up personal distribution of hand sanitizer and masks to drivers at their truck stop at I-10 and U.S. Highway 301 in Jacksonville.

Most Americans want to give back and say Thank you to the truckers that keep the shelves stocked and the country moving, Rob Hooper, Atlantic Logistics CEO, said in a statement. Im so proud of the initiative our employees took to help make these folks lives a little safer and simpler.

Back to index

Volunteers from the North American technology community have banded together to build a mobile app that helps truck drivers find essential services near their current locations, so they can continue operating safely during the Covid-19 pandemic.

Known as Truckers Welcome, the site serves as a social application that lets businesses add and share information about the services they are still able to provide to driverssuch as drive-through meals, washrooms, Wi-Fi, and fuel. With over 1,600 locations registered across the U.S. and Canada since it launched, the site addresses some of the significant challenges truck drivers face while on the road keeping goods and supplies flowing to grocery stores, hospitals, and communities, its creators say.

Back to index

Third-party logistics service provider (3PL) Logistics Plus Inc. provided free customs clearance and delivery services to transport a load of 50,000 surgical masks for the city of Erie, Pennsylvania.

The masks were originally donated by Eries sister city, Zibo, China, and airfreighted to Chicago. Erie-based Logistics Plus then facilitated the customs clearance and paperwork, took possession of the shipment, and arranged complimentary transportation of the goods from Chicago to Erie.

Together we are Erie Strong, Jim Berlin, founder and CEO of Logistics Plus, said in a release. Helping [Erie] Mayor [Joe] Schember and the city get these masks from Chicago to Erie and in the hands of our front-line government workers was an easy decision. It feels good to donate and to do something for those in need.

Back to index

The Raymond Corp. put its weight into the Covid-19 fight to help local health-care workers and first responders. The New York-based maker of forklifts and other material handling equipment and solutions used its engineering might to 3D print and assemble face shields at its Greene, New York, facility. Company President and CEO Mike Field said in April that Raymond would produce 2,000 face shields to be distributed to local hospitals and first responders.

Like everyone, we at Raymond have heard the appeals for protective equipment from our local health-care workers battling the Covid-19 pandemic, Field said in a release. Raymond has the ability and desire to utilize our vast production capabilities to support those crucial employees. ... We will continue to monitor the evolving situation to determine how best we can support our local health-care heroes.

Back to index

Supply chain technology and risk management firm Resilinc responded early to increased demand for critical health-care supplies by launching the The Exchange at Resilinc, an online clearinghouse designed to match available inventory with hospitals that need items, including personal protective equipment, to fight the Covid-19 pandemic. The company announced the initiative March 25, and the exchange was up and running by mid-April.

Resilinc partnered with representatives from the health-care and logistics sectors to create the exchange, which will allow group purchasing organizations (GPOs), distributors, and hospitals to connect and exchange inventory and to access donated inventory from manufacturers and other organizations. The program is designed to digitize and broaden a system that is largely done informally and manually between trading partners. The exchange will be free for all U.S. hospitals through September, according to Resilinc Founder and CEO Bindiya Vakil.

Back to index

The American Trucking Associations (ATA) joined with corporate partners to further its #thankatrucker campaign, launching its Providing for the Frontlines initiative in May.

Insurance provider OneBeacon, U.S. Bank, Michelin, and Hydro-Chem Systems are partnering with ATA to provide hand sanitizer nationwide as well as meals for professional truck drivers on the road, the groups said.

This new initiative aims to celebrate unsung heroes in the trucking industry who continue to bravely deliver Americas goods throughout the ongoing coronavirus pandemic, as well as provide relief to the hard-working men and women behind the wheel, Arlington, Virginia-based ATA said in a statement.

The initiative will include a photo contest in which drivers can submit a fun photo of themselves and their rig. Once submitted, they will be entered into a drawing to win a $25 electronic gift card for a meal of the drivers choice while on the road. Multiple winners will be selected daily. Truckers can enter and anyone can view the daily winners at http://www.trucking.org/thankatrucker.

Providing for the Frontlines builds on ATAs efforts to support truckers nationwide. Also in May, the association teamed up with Protective Insurance and ABF Freight to supply 550 gallons of hand sanitizer to eight states across the country. By mid-month, thousands of drivers had been able to refill their personal supply at no cost to them, ATA said.

Back to index

Logistics robot technology provider Brain Corp. is donating $1.6 million worth of autonomous floor-cleaning robots and services to essential businesses during the Covid-19 pandemic.

Autonomous mobile robots (AMRs) are playing a vital role in helping support essential businesses and their workers on the front lines of the health crisis, since retailers, airports, and hospitals are required to clean more frequently and deliver more cleaning coverage than usual. Autonomous floor scrubbers powered by Brain Corp.s BrainOS software are providing more than 8,000 hours of daily workequal to a quarter-million hours throughout the month of Maythat otherwise would have to be done by an essential worker, the company said.

Back to index

Transport and logistics firms Gebrder Weiss and Delta Group Logistics teamed up to deliver thousands of pieces of personal protective equipment (PPE) to health and safety workers in the Chicago area as they continued to fight the Covid-19 pandemic in May.

The companies purchased and distributed 8,000 face masks and 1,000 face shields to various organizations and companies in Chicago and the surrounding suburbs. A majority of the face shields donated went directly to Springfield, Illinois, to help stock the Centers for Medicare & Medicaid Services state surplus warehouse so that shields are ready when they are needed, the companies said.

The companies planned to continue donating PPE throughout the month.

Separately, Illinois-based Seko Logistics has stepped up its own PPE efforts with donations for front-line workers and by providing additional equipment for its own essential workforce, the company said.

As of mid-May, Seko Logistics had distributed more than 28,000 face masks and 138,000 gloves to its front-line teams in North America along with additional PPE kits for its MedTec drivers, which support medical deliveries nationwide. That comes on top of a pledge to donate $200,000 for the purchase of PPE for health-care workers treating Covid-19 patients around the country.

Back to index

Liquid and powder coatings supplier Axalta has shifted the manufacturing capabilities of its facility in Tlalnepantla, Mexico, to produce more than 1,000 liters (264 gallons) of hand sanitizer, which is being donated to local health-care facilities, first responders, and other essential businesses.

These efforts complement Axaltas global support of coronavirus relief efforts, which include sending personal protective equipment (PPE) to hospitals in the U.S., France, Belgium, and Germany, and providing more than 5,000 seat covers to medical professionals, who can use the seat covers in their own cars to reduce the risk of transmitting the coronavirus when they are visiting those infected with the virus.

Back to index

Aerospace and defense contractor Lockheed Martin Corp. has donated cargo capacity on its corporate aircraft as an in-kind donation to support the federal governments Covid-19 response for medical transplants, helping ensure that the life-saving products from European donors reach American patients on time.

The flights help ensure the timely delivery of bone marrow and blood stem cells for transplant, a need that arose when the National Marrow Donor Program (NMDP)/Be The Match ran out of available European Union couriers to deliver life-saving cells to U.S. patients, since tens of thousands of commercial flights had been canceled during the pandemic. Lockheed Martin will be providing weekly air transport based on government medical needflying government medical teams to the most critical, high-priority locations around the country and/or flying to support bone-marrow transport to help with the governments coronavirus response.

Back to index

Chocolate maker The Hershey Co. has committed $1 million to acquire, install, and staff a new manufacturing line dedicated to the production of face masks during the Covid-19 emergency.

Leveraging its internal engineering capabilities and its relationships with equipment manufacturer JR Automation and General Motors, which is making similar masks, the company is moving quickly to address the nationwide shortage of protective equipment. When it becomes operational, the Hershey, Pennsylvania-based line will be capable of producing up to 45,000 masks per day, the company said in mid-May.

Back to index

Transportation and logistics services provider DHL Global Forwarding, packaging and design venture Royal Bay, and tracking technology firm LocatorX have stepped up to provide personal protective equipment (PPE) and other services to front-line workers.

DHL Global Forwarding is partnering with customers in the health-care industry to ship more than 100 tons per week of medical supplies, equipment parts, pharmaceuticals, and protective clothing for hospitals, health-care workers, and patients throughout the United States and is also offering special charters to and from China to ease the capacity crunch for customers, officials said in May.

Royal Bay, a joint venture between packaging and design companies Bay Cities and The Royal Group, is assembling and packaging 2 million face shields for essential workers. The shields will be distributed to medical suppliers and distributors, who will send them to medical facilities and hospitals nationwide. At capacity, Royal Bay will assemble and package 500,000 units per week, the companies said.

Atlanta-based tracking technology firm LocatorX has launched a National Medical Device Registry allowing hospitals to log their life-saving equipment at no cost during the Covid-19 crisis. The registry will also help hospitals quickly and easily identify the status of venilators available for loan, the company said.

Read more:
Heroes of the Supply Chain | 2020-06-25 - DC Velocity

The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

Continued here:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News

Amir Hashemi,1 Masoumeh Ezati,2 Javad Mohammadnejad,3 Behzad Houshmand,4 Shahab Faghihi5

1Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 2Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran; 3Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 4Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran; 5Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran

Correspondence: Javad Mohammadnejad; Shahab Faghihi Tel +9821 8609-3078Tel/ Fax +98 21 44787386Fax +98(21)88497324Email mohamadnejad@ut.ac.ir; sfaghihi@nigeb.ac.ir

Background: Ineffective integration has been recognized as one of the major causes of early orthopedic failure of titanium-based implants. One strategy to address this problem is to develop modified titanium surfaces that promote osteoblast differentiation. This study explored titanium surfaces modified with TiO2 nanotubes (TiO2 NTs) capable of localized drug delivery into bone and enhanced osteoblast cell differentiation.Materials and Methods: Briefly, TiO2 NTs were subjected to anodic oxidation and loaded with Metformin, a widely used diabetes drug. To create surfaces with sustainable drug-eluting characteristics, TiO2 NTs were spin coated with a thin layer of chitosan. The surfaces were characterized via scanning electron microscopy, atomic force microscopy, and contact angle measurements. The surfaces were then exposed to mesenchymal bone marrow stem cells (MSCs) to evaluate cell adhesion, growth, differentiation, and morphology on the modified surfaces.Results: A noticeable increase in drug release time (3 days vs 20 days) and a decrease in burst release characteristics (85% to 7%) was observed in coated samples as compared to uncoated samples, respectively. Chitosan-coated TiO2 NTs exhibited a considerable enhancement in cell adhesion, proliferation, and genetic expression of type I collagen, and alkaline phosphatase activity as compared to uncoated TiO2 NTs.Conclusion: TiO2 NT surfaces with a chitosan coating are capable of delivering Metformin to a bone site over a sustained period of time with the potential to enhance MSCs cell attachment, proliferation, and differentiation.

Keywords: titania nanotubes, titanium, osteogenic differentiation, anodization, mesenchymal bone marrow stem cells, MSCs

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:
Chitosan Coating of TiO2 Nanotube Arrays for Improved Metformin Releas | IJN - Dove Medical Press

2020 World Sickle Cell Day: Symptoms of sickle cell can appear around 5 months of age

World Sickle Cell Day is observed on June 19. The day is meant to raise awareness about sickle cell disease, which is a group of disorders that affect haemoglobin, the molecule in red blood cells which deliver oxygen to cells throughout the body. People with this disorder have haemoglobin S, an atypical haemoglobin molecule which can distort red blood cells into a sickle or a crescent shape. This disease is a blood disorder which is inherited and passed down from parents to the child. In 2008, the UN General Assembly recognised sickle cell disease as a public health problem, and one of the world's foremost genetic diseases.

Symptoms of sickle cell disease usually appear around five months of age. The symptoms vary from person to person and change over time.

Symptoms of sickle cell disease can appear from two to five months of age. But in milder cases, the symptoms may appear till teenage.

Sickle cell disease can cause vision problemsPhoto Credit: iStock

Also read:These Iron-Packed Foods Can Combat Anemia And Other Health Problems

One can get infected with sickle cell disease if both parents have the problem gene and pass it on to their child.

1. HbSS or sickle cell anemia is a severe kind of sickle cell disease. It occurs when child inherits sickle cell gene from each parent.

2. HbSc occurs when one parents has sickle cell gene and the other has a gene from abnormal haemoglobin.

3. Hbs beta thalassemia occurs when sickle cell gene is passed from one parent, and beta-thalassemia is passed on from the other.

If only one parent has the problem gene, then the child will not have symptoms but will have the gene known as sickle cell trait.

Also read:Anemia During Pregnancy: Symptoms, Risk Factors And Prevention Steps Every Woman Must Know

Sickle cell can be detected in an infant during newborn screening process. In case of family history, it can be detected during pregnancy.

Bone marrow or stem cell transplant is the only permanent cure for sickle cell disease. Early detection and timely treatment can help in managing symptoms, offer relief from pain and prevent severe complications.

Apart from stem cell transplant, the symptoms can be managed with the help of periodic blood transfusion, pain killers, vaccinations and antibiotics.

Also read:6 Side-Effects Of Overuse Of Antibiotics And Home Remedies By Rujuta Diwekar That Can Be As Effective

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Follow this link:
World Sickle Cell Day 2020: Know The Types, Symptoms, Causes And Treatment - NDTV

The global Rheumatoid Arthritis Stem Cell Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Rheumatoid Arthritis Stem Cell Therapy market player in a comprehensive way. Further, the Rheumatoid Arthritis Stem Cell Therapy market report emphasizes the adoption pattern of the Rheumatoid Arthritis Stem Cell Therapy across various industries.Request Sample Reporthttps://www.factmr.com/connectus/sample?flag=S&rep_id=1001The Rheumatoid Arthritis Stem Cell Therapy market report highlights the following players:The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

The Rheumatoid Arthritis Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.Important regions covered in the Rheumatoid Arthritis Stem Cell Therapy market report include:

North America (U.S., Canada)Latin America (Mexico, Brazil)Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)Eastern Europe (Russia, Poland, Rest Of Eastern Europe)Asia Pacific Excluding Japan (China, India, Australia & New Zealand)JapanMiddle East and Africa (GCC, S. Africa, Rest Of MEA)

The Rheumatoid Arthritis Stem Cell Therapy market report takes into consideration the following segments by treatment type:

Allogeneic Mesenchymal stem cellsBone marrow TransplantAdipose Tissue Stem Cells

The Rheumatoid Arthritis Stem Cell Therapy market report contain the following distribution channel:

HospitalsAmbulatory Surgical CentersSpecialty ClinicsHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=1001

Buy the report at a discounted rate!!! Exclusive offer!!!

The Rheumatoid Arthritis Stem Cell Therapy market report offers a plethora of insights which include:

Changing consumption pattern among individuals globally.Historical and future progress of the global Rheumatoid Arthritis Stem Cell Therapy market.Region-wise and country-wise segmentation of the Rheumatoid Arthritis Stem Cell Therapy market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global Rheumatoid Arthritis Stem Cell Therapy market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global Rheumatoid Arthritis Stem Cell Therapy market.

The Rheumatoid Arthritis Stem Cell Therapy market report answers important questions which include:

Which regulatory authorities have granted approval to the application of Rheumatoid Arthritis Stem Cell Therapy in Health industry?How will the global Rheumatoid Arthritis Stem Cell Therapy market grow over the forecast period?Which end use industry is set to become the leading consumer of Rheumatoid Arthritis Stem Cell Therapy by 2028?What manufacturing techniques are involved in the production of the Rheumatoid Arthritis Stem Cell Therapy?Which regions are the Rheumatoid Arthritis Stem Cell Therapy market players targeting to channelize their production portfolio?Get Full Access of the Report @https://www.factmr.com/report/1001/rheumatoid-arthritis-stem-cell-therapy-market

Pertinent aspects this study on the Rheumatoid Arthritis Stem Cell Therapy market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Rheumatoid Arthritis Stem Cell Therapy market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Rheumatoid Arthritis Stem Cell Therapy market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Rheumatoid Arthritis Stem Cell Therapy market? Which key end-use industry trends are expected to shape the growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market? What factors will promote new entrants in the Rheumatoid Arthritis Stem Cell Therapy market? What is the degree of fragmentation in the Rheumatoid Arthritis Stem Cell Therapy market, and will it increase in coming years?Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

View post:
Rheumatoid Arthritis Stem Cell Therapy Market Future Innovation Strategies, Growth & Profit Analysis, Forecast by 2028 - The Cloud Tribune